Journal of Neuro-Oncology

, Volume 55, Issue 2, pp 91–100

Monoclonal Antibodies to Vascular Endothelial Growth Factor (VEGF) And the VEGF Receptor, FLT-1, Inhibit the Growth of C6 Glioma in a Mouse Xenograft

  • David F. Stefanik
  • Wendy K. Fellows
  • Laila R. Rizkalla
  • Waheeb M. Rizkalla
  • Paulette P. Stefanik
  • Albert B. Deleo
  • William C. Welch
Article

DOI: 10.1023/A:1013329832067

Cite this article as:
Stefanik, D.F., Fellows, W.K., Rizkalla, L.R. et al. J Neurooncol (2001) 55: 91. doi:10.1023/A:1013329832067

Abstract

Monoclonal antibodies raised to peptide sequences of vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibited the growth of C6 tumors growing subcutaneously in nude mice. Immunohistochemical analysis demonstrated antibody targeting of blood vessels, tumor cells, and macrophages. A control antibody demonstrated no growth inhibition or tumor uptake. An antibody to FLT-1 impaired microvascular maturation and diminished the accumulation of tumor infiltrating macrophages. The antibodies demonstrated affinity for microvasculature and tumor cells in immunohistochemistry of human glioblastoma multiforme. Targeting VEGF and its receptors has potential in the treatment of tumors of the central nervous system. FLT-1 presents an attractive target due to its presence on multiple cell types.

monoclonal antibodies angiogenesis VEGF FLT-1 C6 glioma 

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • David F. Stefanik
    • 1
  • Wendy K. Fellows
    • 2
  • Laila R. Rizkalla
    • 1
  • Waheeb M. Rizkalla
    • 3
  • Paulette P. Stefanik
    • 1
  • Albert B. Deleo
    • 4
  • William C. Welch
    • 2
  1. 1.Department of Radiation OncologyLaurel Highlands Cancer ProgramUSA
  2. 2.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  3. 3.Department of PathologyConemaugh Memorial Medical CenterJohnstown
  4. 4.University of Pittsburgh Cancer InstituteUSA

Personalised recommendations